NCT07092748View on ClinicalTrials.gov

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions

Advanced Solid Cancers

Interventions

DRUG

HS387

HS387 tablets will be given orally

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Hisun Pharmaceutical Co. Ltd.

INDUSTRY